Variable expression and function of the cytochrome P4502D6 (CYP2D6) leads to distinct
phenotypes termed ultrarapid (UM), extensive (EM), intermediate (IM) and poor metabolizer …

Over 40 cytochrome P450 (CYP) 2D6 allelic variants have been discovered thus far. The
alleles may be classified on the basis of the level of activity for which they encode CYP2D6 …

Objective: To determine and compare the cytochrome P450 (CYP) 2C9, CYP2C19 and
CYP2D6 allele and genotype frequencies in the Ashkenazi Jewish (AJ) population with …

Background. Pharmacogenetic testing is used to reveal genetic causes of variation in drug
response. There is limited documentation of the usefulness of this kind of testing in ordinary …

Abstract Cytochrome P4502D6 (CYP2D6) genotyping reliably predicts poor metabolizer
phenotype in Caucasians, but is less accurate in African Americans. To evaluate …

Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse
effects of drug therapies. The majority of hepatically cleared drugs are metabolized by …

Abstract CYP2D6 metabolizes nearly 25% of clinically used drugs. Genetic polymorphisms
cause large inter-individual variability in CYP2D6 enzyme activity and are currently used as …

CYP2D6 is a highly polymorphic enzyme that mediates the metabolism of around 20% of all
currently prescribed drugs. Genetic variability within CYP2D6 results in poor (PM) …

The cytochrome P450 (CYP) enzyme system is involved in the metabolism and elimination
of numerous widely used drugs. The capacity of this system varies from one person to …

Polymorphic expression of CYP2D6 contributes to the wide range of activity observed for
this clinically important drug metabolizing enzyme. In this report we describe novel …